Melatonin, human aging, and age-related diseases.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or primary empirical data.
PubMed 15582288 · doi:10.1016/j.exger.2004.04.012
What was done
This narrative review synthesized literature on the role of the pineal hormone melatonin in human aging, circadian rhythm regulation, immune function, oxidative stress, and age-associated conditions.
What was found
The abstract reports no quantitative data or statistical comparisons. It describes an age-related decline in endogenous melatonin levels associated with reduced sleep efficiency and disrupted circadian rhythms. Melatonin acts as an immunomodulator and free-radical scavenger. Current evidence does not support melatonin as an agent that extends lifespan or reverses aging, though it may provide symptomatic benefits for sleep disruption, circadian misalignment, and age-related diseases in older populations.
Why it matters
It outlines the biological rationale for testing melatonin supplementation as a supportive intervention for sleep and circadian health in aging populations without endorsing anti-aging claims.
Limits
The paper is a non-systematic narrative review with no defined search protocol, study quality assessments, or quantitative effect sizes reported in the abstract. Specific clinical trial cohorts, doses, and outcome measurements are not provided.
Cited by
- context Endogenous melatonin production in the human body begins to decline around age 50.